Clinical Trials Browser

NIH × Interventional × ganitumab × Clear all

NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase 3 Active not recruiting

312 enrolled 14 charts

Sarcoma, Ewing

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00562380 2013-07-18

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Phase 1 Completed

DermatologicGenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Prostatic Neoplasms, Sarcoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Neuroectodermal Tumors, Primitive, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Desmoplastic Small Round Cell Tumor